Cocrystal Pharma doses first subjects in Phase 1b norovirus challenge study for CDI-988

Cocrystal Pharma, Inc.

First subjects dosed in Phase 1b challenge study (NCT07198139) at Emory University evaluating CDI-988 for norovirus prevention and treatment.
CDI-988 is a direct-acting oral antiviral targeting 3CL protease; no approved norovirus treatments or vaccines exist.
Study to enroll up to 40 healthy subjects; primary endpoint is reduction of clinical symptoms vs placebo.
CDI-988 previously showed favorable safety in Phase 1; global norovirus economic burden estimated at $60B annually.
FDA issued Study May Proceed Letter in Sep 2025; Emory IRB approval obtained Dec 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.